May 3, 2011 — A guideline document from the American Society of Echocardiography (ASE) which makes recommendations for the use of current imaging modalities in optimizing the management of patients with hypertrophic cardiomyopathy (HCM) has been published in the May issue of JASE, the Journal of the ASE. “The document includes the recommendations for the role of imaging in the diagnosis and followup of patients with hypertrophic cardiomyopathy, including risk stratification for sudden cardiac death,” explained writing group chair Sherif F. Nagueh, M.D., FASE, professor of medicine at Weill Cornell Medical College and the medical director of the Methodist DeBakey Heart & Vascular Center Echocardiography laboratory in Houston, Texas.

Advances in cardiac imaging have brought an increasing complexity of imaging choices for busy clinicians to consider. Clinicians can image the heart using ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) or nuclear cardiology techniques. Physicians need to make appropriate choices among the imaging options to avoid duplicate testing or getting studies which don’t address the clinical question.

Unlike many guideline documents, which focus on a specific type of cardiac imaging, this paper brings together experts across all types of cardiac imaging to focus on a specific clinical disorder. This guideline reviews the strengths and weakness of the different ways to image the heart in patients with HCM. By taking a critical look at the most commonly used cardiac imaging modalities and most common clinical questions in patients with HCM, this guideline should prove to be a valuable resource.

HCM is the most common genetic cardiomyopathy, affecting about 0.2 percent of people across multiple geographies and ethnicities. While a majority of patients with HCM have a near normal lifespan, adverse outcomes, including life-limiting symptoms and sudden cardiac death, occur in some people.

The recommendations were endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. The full document is available at www.asecho.org/guidelines.

The American Society of Echocardiography (ASE) is a professional organization of physicians, cardiac sonographers, nurses and scientists involved in echocardiography, the use of ultrasound to image the heart and cardiovascular system. The organization was founded in 1975 and is the largest international organization for cardiac imaging.

For more information: www.asecho.org


Related Content

News | Artificial Intelligence

Nov. 20, 2025 — Aidoc has announced a collaboration with AdventHealth to launch one of the largest imaging AI ...

Time November 21, 2025
arrow
News | Radiology Business

Nov. 13, 2025 — Covera Health recently announced that Advanced Radiology Services (ARS) has joined its national Quality ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Orthopedic Imaging

Nov.10, 2025 — Medical imaging technology company Adaptix Ltd. has received 510(k) clearance from the U.S. Food and Drug ...

Time November 11, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

Nov. 10, 2025 — There has been substantial progress in the past few years in the field of MRI in general and remote MR ...

Time November 11, 2025
arrow
News | Contrast Media

Nov. 10, 2025 — Scientists at the University of Birmingham have developed a new class of MRI contrast agents – improving ...

Time November 10, 2025
arrow
News | RSNA 2025

Oct. 31, 2025 — Echolight plans to demonstrate its bone density scanning technology at the Radiological Society of North ...

Time November 03, 2025
arrow
News | X-Ray

Oct. 30, 2025 – In collaboration with OBIO, University Health Network (UHN), Canada’s leading hospital and the No. 1 ...

Time November 03, 2025
arrow
News | Magnetic Resonance Imaging (MRI) | Children's Hospital Los Angeles

Oct. 28, 2025 — Bronchopulmonary dysplasia (BPD) is the most common — and most serious — complication of extreme ...

Time October 31, 2025
arrow
News | FDA

Oct. 30, 2025 — Sirona Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sirona ...

Time October 30, 2025
arrow
Subscribe Now